Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 3;72(1):47–54. doi: 10.1538/expanim.22-0057

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 Japanese Association for Laboratory Animal Science

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)

PMC Copyright notice

Fig. 1. — Survivors and clinical symptoms in adriamycin (ADR)-treated mice. (A) Log-rank survival analysis of B6-Prkdc^R2140C and BALB/c mice. ADR-treated BALB/c (n=11) and B6-Prkdc^R2140C (n=14) mice were analyzed. (B and C) Urinary albumin quantified by Coomassie brilliant blue (CBB) staining was corrected for creatinine (Cre). ADR-treated BALB/c (n=6) and B6-Prkdc^R2140C (n=10) mice, and non-treated BALB/c (n=4) and B6-Prkdc^R2140C (n=4) mice were analyzed. (D and E) Serum from the collected blood was separated and subjected to biochemical tests; blood urea nitrogen (BUN) and Cre levels in the blood were evaluated. ADR-treated BALB/c (n=6) and B6-Prkdc^R2140C (n=10) mice, and non-treated BALB/c (n=4) and B6-Prkdc^R2140C (n=4) mice were analyzed. Data are expressed as mean ± SD. *P<0.05.